Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Genetic structure of the Canarian palm tree (Phoenix canariensis) at the island scale: does the "island within islands" concept apply to species with high colonization abilities?

Saro I, García-Verdugo C, González-Pérez MA, Naranjo A, Santana A, Sosa PA.

Plant Biol (Stuttg). 2018 Sep 19. doi: 10.1111/plb.12913. [Epub ahead of print]

PMID:
30230155
2.

Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS.

Naranjo A, Ojeda-Bruno S, Saavedra A, Molina A, Negrín M.

Expert Rev Pharmacoecon Outcomes Res. 2018 Sep 6:1-7. doi: 10.1080/14737167.2018.1513791. [Epub ahead of print]

PMID:
30129375
3.

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL.

Front Immunol. 2018 Jul 16;9:1641. doi: 10.3389/fimmu.2018.01641. eCollection 2018.

4.

Human Corneal Changes After Rose Bengal Photodynamic Antimicrobial Therapy for Treatment of Fungal Keratitis.

Martinez JD, Naranjo A, Amescua G, Dubovy SR, Arboleda A, Durkee H, Aguilar MC, Flynn HW, Miller D, Parel JM.

Cornea. 2018 Oct;37(10):e46-e48. doi: 10.1097/ICO.0000000000001701. No abstract available.

PMID:
30028750
5.

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL.

Front Immunol. 2018 Jun 18;9:1355. doi: 10.3389/fimmu.2018.01355. eCollection 2018. Erratum in: Front Immunol. 2018 Jul 16;9:1641.

6.

[Tricuspid valve endocarditis in a non-drug-addicted patient with no prior predisposing cardiopathy].

Naranjo A, Ruiz D, Pérez A.

Arch Cardiol Mex. 2018 Jul - Sep;88(3):245-247. doi: 10.1016/j.acmx.2018.02.006. Epub 2018 Mar 23. Spanish. No abstract available.

PMID:
29580915
7.

Kienböck Disease With Ultrasonographic Findings of Wrist Arthritis.

Greco M, Quevedo JC, Francisco F, Ghiglione S, Marrero T, Naranjo A.

J Clin Rheumatol. 2018 Mar 13. doi: 10.1097/RHU.0000000000000753. [Epub ahead of print] No abstract available.

PMID:
29538085
8.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.

Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

9.

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL.

Lancet Child Adolesc Health. 2018 Jan;2(1):25-34. doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3.

PMID:
29376112
10.

Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.

Naranjo A, Fernández-Conde S, Ojeda S, Torres-Hernández L, Hernández-Carballo C, Bernardos I, Rodríguez S, Laynez P.

Arch Osteoporos. 2017 Dec 11;12(1):112. doi: 10.1007/s11657-017-0373-9.

PMID:
29230540
11.

Immune-Enhancing Formulas for Patients With Cancer Undergoing Esophagectomy: Systematic Review Protocol.

Naranjo A, Isenring E, Teleni L.

JMIR Res Protoc. 2017 Nov 17;6(11):e214. doi: 10.2196/resprot.7688.

12.

Recommendations for the use of methotrexate in psoriatic arthritis.

Cañete JD, Ariza-Ariza R, Bustabad S, Delgado C, Fernández-Carballido C, García Llorente JF, Loza E, Montilla C, Naranjo A, Pinto JA, Queiro R, Ramírez J, Tornero-Molina J.

Reumatol Clin. 2018 Jul - Aug;14(4):183-190. doi: 10.1016/j.reuma.2017.08.011. Epub 2017 Oct 17. English, Spanish.

13.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

14.

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.

Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, Oudoux A, Śliwińska A, Taborska K, Biassoni L, Yanik GA, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, Matthay KK, Park JR, Kreissman SG, Valteau-Couanet D, Boubaker A.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):292-305. doi: 10.1007/s00259-017-3829-7. Epub 2017 Sep 23.

15.

Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.

Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK.

J Nucl Med. 2018 Mar;59(3):502-508. doi: 10.2967/jnumed.117.195883. Epub 2017 Sep 8.

16.

Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.

Sarens IL, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Dick AD, Espada G, Fernandez-Martin J, Guly CM, Hachulla E, Harjacek M, Khubchandani R, Mackensen F, Merino R, Modesto C, Naranjo A, Oliveira-Knupp S, Özen S, Pajot C, Ramanan AV, Russo R, Susic G, Thatayatikom A, Thomée C, Vastert S, Bertin J, Arostegui JI, Rose CD, Wouters CH.

Am J Ophthalmol. 2018 Mar;187:158-166. doi: 10.1016/j.ajo.2017.08.017. Epub 2017 Sep 6.

PMID:
28887115
17.

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR.

Cancer. 2017 Dec 15;123(24):4914-4923. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. Review.

PMID:
28885700
18.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG.

Cancer. 2017 Nov 1;123(21):4224-4235. doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

PMID:
28696504
19.

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM.

Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017.

20.

Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.

Khan NA, Spencer HJ, Nikiphorou E, Naranjo A, Alten R, Chirieac RM, Drosos AA, Géher P, Inanc N, Kerzberg E, Ancuta CM, Müller R, Ørnbjerg L, Sokka T.

Rheumatology (Oxford). 2017 Aug 1;56(8):1395-1400. doi: 10.1093/rheumatology/kex076.

PMID:
28575509
21.

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R.

Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23.

22.

Different expression levels of DLK1 inversely modulate the oncogenic potential of human MDA-MB-231 breast cancer cells through inhibition of NOTCH1 signaling.

Nueda ML, Naranjo AI, Baladrón V, Laborda J.

FASEB J. 2017 Aug;31(8):3484-3496. doi: 10.1096/fj.201601341RRR. Epub 2017 May 1.

PMID:
28461338
23.

MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

DuBois SG, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D, Kreissman S, Baker DL, Parisi M, Shulkin BL, Bai H, Diskin SJ, Batra V, Maris JM, Park JR, Matthay KK, Yanik G.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26545. Epub 2017 Apr 6.

PMID:
28383813
24.

Androgen deprivation in prostate cancer and the long-term risk of fracture.

Ojeda S, Lloret M, Naranjo A, Déniz F, Chesa N, Domínguez C, Lara PC.

Actas Urol Esp. 2017 Oct;41(8):491-496. doi: 10.1016/j.acuro.2017.01.005. Epub 2017 Mar 1. English, Spanish.

PMID:
28259363
25.

Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ.

Eur J Cancer. 2017 Feb;72:177-185. doi: 10.1016/j.ejca.2016.11.022. Epub 2016 Dec 26.

26.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B.

N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.

27.

Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.

Galli S, Naranjo A, Van Ryn C, Tilan JU, Trinh E, Yang C, Tsuei J, Hong SH, Wang H, Izycka-Swieszewska E, Lee YC, Rodriguez OC, Albanese C, Kitlinska J.

Am J Pathol. 2016 Nov;186(11):3040-3053. doi: 10.1016/j.ajpath.2016.07.019. Epub 2016 Oct 12.

28.

A2AR Binding Kinetics in the Ligand Depletion Regime.

McNeely PM, Naranjo AN, Forsten-Williams K, Robinson AS.

SLAS Discov. 2017 Feb;22(2):166-175. doi: 10.1177/1087057116667256. Epub 2016 Sep 27.

29.

A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group.

Mazul AL, Siega-Riz AM, Weinberg CR, Engel SM, Zou F, Carrier KS, Basta PV, Vaksman Z, Maris JM, Diskin SJ, Maxen C, Naranjo A, Olshan AF.

Cancer Causes Control. 2016 Oct;27(10):1209-18. doi: 10.1007/s10552-016-0799-1. Epub 2016 Aug 19.

30.

Impact of purification conditions and history on A2A adenosine receptor activity: The role of CHAPS and lipids.

Naranjo AN, McNeely PM, Katsaras J, Robinson AS.

Protein Expr Purif. 2016 Aug;124:62-7. doi: 10.1016/j.pep.2016.05.015. Epub 2016 May 27.

31.

Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group.

Ehrlich PF, Hamilton TE, Gow K, Barnhart D, Ferrer F, Kandel J, Glick R, Dasgupta R, Naranjo A, He Y, Perlman EJ, Kalapurakal JA, Khanna G, Dome JS, Geller J, Mullen E.

Pediatr Blood Cancer. 2016 Nov;63(11):1905-10. doi: 10.1002/pbc.26083. Epub 2016 May 27.

32.

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ.

Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.

33.

Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study).

Piqué N, Ponce M, Garrigues V, Rodrigo L, Calvo F, de Argila CM, Borda F, Naranjo A, Alcedo J, José Soria M, Rey E, Bujanda L, Gisbert JP, Suarez D, Calvet X, Ponce J; PRESS Study Group.

United European Gastroenterol J. 2016 Apr;4(2):229-35. doi: 10.1177/2050640615595916. Epub 2015 Jul 24.

34.

Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1396. No abstract available.

PMID:
27044383
35.

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.

Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons KA, States LJ, Rojas Y, Miller A, Volchenboum SL, Simon T, Krug B, Sarnacki S, Valteau-Couanet D, von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J.

J Clin Oncol. 2016 Mar 1;34(7):740-6. doi: 10.1200/JCO.2015.63.2042. Epub 2016 Jan 11.

36.

Coarse-grained molecular dynamics simulation of water diffusion in the presence of carbon nanotubes.

Lado Touriño I, Naranjo AC, Negri V, Cerdán S, Ballesteros P.

J Mol Graph Model. 2015 Nov;62:69-73. doi: 10.1016/j.jmgm.2015.09.009. Epub 2015 Sep 11.

PMID:
26386454
37.

Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):474-481. doi: 10.1007/s00259-015-3179-2. Epub 2015 Sep 4. Erratum in: Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1396.

38.

Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice.

Naranjo A, Cáceres L, Hernández-Beriaín JÁ, Francisco F, Ojeda S, Talaverano S, Nóvoa-Medina J, Martín JA, Delgado E, Trujillo E, Álvarez F, Magdalena L, Rodríguez-Lozano C.

Rheumatol Int. 2015 Nov;35(11):1851-5. doi: 10.1007/s00296-015-3332-z. Epub 2015 Aug 4.

PMID:
26238094
39.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

40.

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC.

Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9.

41.

Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.

Naranjo A, Ojeda-Bruno S, Bilbao-Cantarero A, Quevedo-Abeledo JC, Diaz-González BV, Rodríguez-Lozano C.

Osteoporos Int. 2015 Nov;26(11):2579-85. doi: 10.1007/s00198-015-3185-z. Epub 2015 Jun 6.

PMID:
26048675
42.

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H.

Br J Cancer. 2015 Jun 30;113(1):57-63. doi: 10.1038/bjc.2015.188. Epub 2015 Jun 2.

43.

Secondary fracture prevention after femur fractures in the Gran Canaria North Health Area: A 2004-2014 comparison.

Naranjo A, Ojeda-Bruno S, Bilbao Cantarero A, Rodríguez-Moreno S.

Reumatol Clin. 2016 Jan-Feb;12(1):58. doi: 10.1016/j.reuma.2015.04.003. Epub 2015 May 27. English, Spanish. No abstract available.

44.

Adjustment in the clinical practice of treat-to-target guidelines for rheumatoid arthritis: Results of the ToARCan study.

Naranjo A, Cáceres L, Hernández-Beriaín JÁ, Francisco F, Ojeda S, Talaverano S, Nóvoa-Medina J, Martín JA, Delgado E, Trujillo E, Álvarez F, Magdalena L, Rodríguez-Lozano C.

Reumatol Clin. 2016 Jan-Feb;12(1):34-8. doi: 10.1016/j.reuma.2015.03.003. Epub 2015 Apr 11. English, Spanish.

45.

Recombinant G protein-coupled receptor expression in Saccharomyces cerevisiae for protein characterization.

Blocker KM, Britton ZT, Naranjo AN, McNeely PM, Young CL, Robinson AS.

Methods Enzymol. 2015;556:165-83. doi: 10.1016/bs.mie.2014.12.025. Epub 2015 Mar 20. Review.

PMID:
25857782
46.

Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.

Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, Naranjo A, Dome JS, Perlman EJ.

Cancer. 2015 Jul 15;121(14):2457-64. doi: 10.1002/cncr.29368. Epub 2015 Apr 6.

47.

The teaching of rheumatology at the University. The journey from teacher based to student-centered learning.

Naranjo A, de Toro J, Nolla JM.

Reumatol Clin. 2015 Jul-Aug;11(4):196-203. doi: 10.1016/j.reuma.2014.12.006. Epub 2015 Feb 2. English, Spanish.

48.

Conserved disulfide bond is not essential for the adenosine A2A receptor: Extracellular cysteines influence receptor distribution within the cell and ligand-binding recognition.

Naranjo AN, Chevalier A, Cousins GD, Ayettey E, McCusker EC, Wenk C, Robinson AS.

Biochim Biophys Acta. 2015 Feb;1848(2):603-14. doi: 10.1016/j.bbamem.2014.11.010. Epub 2014 Nov 16.

49.

Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes.

Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Cimaz R, Espada G, Fernandez-Martin J, Hachulla E, Harjacek M, Khubchandani R, Mackensen F, Merino R, Naranjo A, Oliveira-Knupp S, Pajot C, Russo R, Thomée C, Vastert S, Wulffraat N, Arostegui JI, Foley KP, Bertin J, Wouters CH.

Rheumatology (Oxford). 2015 Jun;54(6):1008-16. doi: 10.1093/rheumatology/keu437. Epub 2014 Nov 20.

PMID:
25416713
50.

Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.

Teshiba R, Kawano S, Wang LL, He L, Naranjo A, London WB, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H.

Pediatr Dev Pathol. 2014 Nov-Dec;17(6):441-9. doi: 10.2350/14-06-1505-OA.1. Epub 2014 Sep 10.

Supplemental Content

Loading ...
Support Center